



JFW

PATENT
ATTORNEY DOCKET NO.: 056291-5172

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:)
)
Laurent F. A. HENNEQUIN)
)
Application No.: 10/502,538) Group Art Unit: 1614
)
Filed: July 28, 2004) Examiner: Unassigned
)
FOR: QUINAZOLINE COMPOUNDS)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop ____
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: March 24, 2005

J

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(b)

Attached is a Form PTO-1449 listing the enclosed foreign patent documents.

These references were cited in an International Search Report dated April 24, 2003 in the corresponding PCT application from which the above-identified application is a U.S. national stage application. A copy of that International Search Report was filed in the above-identified application on July 28, 2004.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.


Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5172 and proceed to consider this IDS.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP




By:

Date: March 24, 2005
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

FORM PTO-1449 (modified)

To: U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

Client Ref.

056291-5172

Applicant: HENNEQUIN, Laurent Francois Andre

Appln. No.: 10/502,538

Filing Date: July 28, 2004

Date March 24, 2005

Page 1 of 1

Examiner: Unassigned

Group Art Unit: 1614

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT****U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclosed	No
	GR	0602851 A	06/1994	EP	Zeneca				
	HR	0837063 A	04/1998	EP	Pfizer				
	IR	00/47212 A	08/2000	WIPO	AstraZeneca				
	JR	01/74360 A	10/2001	WIPO	AstraZeneca				
	KR	95/15758 A	06/1995	WIPO	Rhone-Poulenc				
	LR	96/39145 A	12/1996	WIPO	Rhone-Poulenc				
	MR	97/03069 A	01/1997	WIPO	Glaxo				
	NR	99/35132 A	07/1999	WIPO	Glaxo				
	OR								
	PR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	QR								
	RR								
	SR								
	TR								
	UR								
	VR								
	WR								
	XR								

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.